GOTHENBURG, Sweden, March 31, 2025 /PRNewswire/ — Due to a conversion of shares from Series A to Series B in accordance with AB SKF’s Articles of Association, the Company confirms the following.

As per 31 March 2025 there are a total of 455,351,068 shares in AB SKF, out of which 28,930,844 shares are of Series A and 426,420,224 shares are of Series B. The number of votes in the Company amounts to 71,572,866.4.

AB SKF does not hold any own shares.

Aktiebolaget SKF      (publ)

Information in this press release contains information that AB SKF is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication on 31 March 2025 at 08:00 CEST.

For further information, please contact:Press Relations: Carl Bjernstam, +46 31-337 2517; +46 722 201 893; carl.bjernstam@skf.com Investor Relations: Sophie Arnius, +46 31-337 8072; +46 705 908 072; sophie.arnius@skf.com 

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/skf/r/announcement-of-change-in-the-total-number-of-votes-in-ab-skf,c4127503

The following files are available for download:

https://mb.cision.com/Main/637/4127503/3353604.pdf

20250331 Announcement of change in the total number of votes in AB SKF

https://news.cision.com/skf/i/skf-hybrid-ceramic-bearings-collage-jpeg-fullresolution,c3392827

SKF Hybrid ceramic bearings collage jpeg fullresolution

 

Source link

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network
You May Also Like

Asian Art Museum of San Francisco Appoints Dr. Soyoung Lee as Director and CEO

An Esteemed Arts Executive and Trailblazing Asian Art Scholar, Lee will Serve…

JZXN Raises Funds through Convertible Notes to Acquire Bitcoin, Initiating a Strategic Layout of Thousands of Bitcoins

HANGZHOU, China, June 11, 2025 /PRNewswire/ — JZXN Holdings, Inc. (NASDAQ: JZXN; the…

Akeso Announces Completion of Patient Enrollment in Phase III Clinical Trial for Ivonescimab as First-Line Treatment for Biliary Tract Cancer Compared to PD-L1 Therapy

HONG KONG, Sept. 2, 2025 /PRNewswire/ — Akeso (9926.HK) has recently announced…